knowledge -WSS

knowledge

author：explore 2025-10-01 17:19:45 - browse：59662

Illustration of a dollar sign with arrows. — Adobe

Health insurers are telling shareholders that they are ramping up the use of artificial intelligence and are hiring talent to implement the technology across their organizations. They say their artificial intelligence models can increase efficiency and “cut costs,” but they refused to discuss what models they’re using, how those models were developed, or exactly what they’re using them for.

Centene, for instance, says, it is “investing in artificial intelligence and machine learning technologies to improve the health of our members and contain rising healthcare costs.” The insurer, whose plans cover more than 28 million Americans, noted that its large footprint, particularly in government-sponsored programs, puts it “in a unique position to use data to develop models that predict a wide range of health outcomes.”

A STAT review of regulatory filings from publicly traded health insurers showed that several of them, including Elevance, Molina, and Cigna, are investing in AI with the goal of saving money. Elevance has hired nearly 500 people to work exclusively on AI. However, all five of the insurers STAT contacted declined to elaborate on how they are using AI.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

WSS

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Why did Pfizer dish out millions for a Super Bowl ad?

Physician executives need more than on

The future of health care in the House

KalVista pill reduced swelling 'attacks' caused by genetic disease

Chan Zuckerberg Biohub Chicago to focus on inflammation

Wikipedia

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

In age of alternative facts, a scholarly course on calling out crap

Was Amgen transparent enough on FDA's concern on cancer drug?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

PhRMA lawsuit over Medicare drug price negotiation tossed

George Santos makes 1st court appearance after pleading not guilty to 13 counts

FDA rejects Alnylam's heart disease treatment over insufficient data

BioMarin wins approval for gene therapy to treat hemophilia A

Analysis of telehealth claims data suggest service duplication

Medical leaders decry Supreme Court decision on affirmative action

A Q&A with the global head of Boehringer Ingelheim's innovation unit

knowledge

Medical mystery: When a cough is not just a cough

Biogen Alzheimer’s drug launch off to slow start

PhRMA lawsuit over Medicare drug price negotiation tossed

FDA rejects Alnylam's heart disease treatment over insufficient data

Bristol 'take

Vaccine advisory panel ACIP left half staffed by HHS

focus

Wikipedia

leisure time

Wikipedia